captomize limited glp 1 GLP-1 Weight Loss Treatment How to Spot a Fake

Agarwal, A., et al

Klinic ensures that your semaglutide treatment experience is smooth and effective at every stage

PMC: PMC6015571

The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects

Lillys Zepbound, approved in November 2023 as the Indiana-based drug giants answer to Novo Nordisks Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase 3 trial, and a mid-stage study of another Lilly experimental medicine, called retatrutide, showed 24% weight loss after just 48 weeks

Because of this role it is widely associated with fat metabolism and energy production